Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on innovative therapies for neurodegenerative and metabolic disorders, was featured on the latest episode of The BioMedWire Podcast. Co-founder and executive co-chair Anthony Durkacz discussed the company’s lead drug candidate, Lucid-MS, which is being developed to address mobility loss associated with multiple sclerosis (MS) by targeting nerve damage. Durkacz emphasized that current treatments for MS do not adequately address this underlying mechanism, highlighting the potential of Lucid-MS to fill a significant therapeutic gap.
Durkacz also provided an update on the company’s commercial product, unbuzzd(TM), an over-the-counter alcohol metabolism supplement designed to accelerate blood alcohol metabolism. Currently available in the U.S. market, unbuzzd(TM) represents a revenue-generating asset for Quantum BioPharma. The company retains a 19.84% ownership stake in Unbuzzd Wellness Inc., the entity that markets the product, as well as royalty payments: 7% of sales until payments total $250 million, then 3% in perpetuity. This structure provides a steady income stream while Quantum focuses on its pharmaceutical pipeline.
Looking ahead, Quantum BioPharma is preparing for a Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in MS patients. This follows successful Phase 1 testing in healthy volunteers. The trial is a critical milestone, as positive results could position Lucid-MS as a novel therapy for MS-related mobility loss. For more details, the full press release is available at https://ibn.fm/8sLvp.
The company’s broader strategy involves building a portfolio of innovative biotech solutions. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum holds the rights to Lucid-MS, a patented new chemical entity that has shown ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying cause of MS, making Lucid-MS a potential disease-modifying therapy. Additionally, Quantum retains 100% of rights to develop pharmaceutical and medical versions of unbuzzd(TM), expanding its reach beyond the OTC market.
Investors seeking the latest news and updates on QNTM can visit the company’s newsroom at https://ibn.fm/QNTM. The appearance on the BioMedWire Podcast underscores Quantum BioPharma’s commitment to advancing therapies for challenging conditions while leveraging commercial products to support its research pipeline.
